Study to Assess Safety and Effects of Splenic Nerve Stimulation Using the Galvani System in Adults with Active Rheumatoid Arthritis Who Have Not Responded to Biologic or JAK Inhibitor Treatments
Led by Galvani Bioelectronics · Updated on 2024-05-22
28
Participants Needed
14
Research Sites
248 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle using the Galvani System in people with active rheumatoid arthritis RA. Participants must have active RA with an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs DMARDs or JAK inhibitors. The study includes four distinct periods a randomized control trial, an open label phase, a treat-to-target phase, and a long-term follow-up, to thoroughly assess the treatment over time.
Participants who receive the implantable system will be randomly assigned to either active stimulation or sham stimulation for 12 weeks in the first period. In the second period, responders to stimulation continue it, while non-responders or those who had sham stimulation receive an approved RA drug, baricitinib, for 12 weeks. In the third period, participants showing improvement but still with RA symptoms receive combined therapy of stimulation and baricitinib for up to 24 weeks. The fourth period provides a long-term safety follow-up lasting up to 5 years, during which participants may receive stimulation with other standard treatments as judged appropriate.
Throughout the study, participants will undergo assessments including monitoring for adverse events, changes in RA disease activity scores, inflammatory markers, and questionnaires on physical and mental health. The study will track safety and tolerability during each period, with long-term follow-up to observe ongoing effects. The total participation duration extends over several years, with detailed monitoring to evaluate the implantable devices performance and impact on RA symptoms.
CONDITIONS
Brief Title
ConsideRAte Study - Splenic Stimulation for RA
Research Team
O
Operations Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Splenic Stimulation Device (ON)
Sham Splenic Stimulation (OFF)
What is it?
Daily neuromodulation delivered by an implanted splenic stimulation device, intended to modulate immune activity in difficult-to-treat rheumatoid arthritis.
Sham stimulation protocol with identical device placement but no active neuromodulation, acting as a control for device effects.
Role in the trial
Test device effect during sequential randomized period, in participants with inadequate response to prior biologic or JAK inhibitor therapy.
Provides control period to isolate effects of active stimulation versus procedure and device placement.
Primary use
Intended to decrease inflammation and improve clinical outcomes for difficult-to-treat rheumatoid arthritis.
Not intended for clinical benefit; serves as control to compare effects of device activation.
How is it given/performed?
Participants receive daily device activation according to trial protocol during specified periods.
Device is placed and handled as with active stimulation, but no neuromodulation is delivered.
Evidence status
Evidence for effectiveness and safety is limited to early clinical studies, including this randomized feasibility trial. Results from larger studies and longer-term follow-up are still needed.
No clinical benefit is expected; sham stimulation is used only within the trial as a control period.
Important limitations
Limited evidence in small early-stage study, short-term follow-up, and highly selected population with prior biologic/JAKi failure. Longer-term safety and wider efficacy remain uncertain.
Does not represent a clinical care option outside the trial; serves only as procedural control.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 22Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
Rheumatoid arthritis for at least six months as defined by 2010 ACR/EULAR criteria
Male or female participants aged 22 to 75 years
Active rheumatoid arthritis
Inadequate response or intolerance to at least two biologic DMARDs or JAK inhibitors, including at least one TNF inhibitor
Appropriate washout period from previously used biologic DMARDs or JAK inhibitors
Currently receiving stable doses of conventional synthetic DMARDs or have documented history of failure due to ineffectiveness or intolerance
You will not qualify if you...
Unable to provide informed consent
Significant psychiatric disease or substance abuse
History of unilateral or bilateral vagotomy
Active or latent tuberculosis
Known HIV infection; current acute or chronic hepatitis B or C; previous hepatitis B
Positive COVID-19 PCR test at screening
Implanted electrically active medical devices such as pacemakers or defibrillators
Previous removal of the spleen (splenectomy)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Treatment - Period 1
Duration - 12 weeks
Participants receive either active or sham splenic nerve stimulation for rheumatoid arthritis.
Visits as required for device implantation and monitoring during the 12 weeks
Treatment - Period 2
Duration - 12 weeks
Participants enter an open-label phase where they receive active stimulation or an approved rheumatoid arthritis drug based on their response in Period 1.
Visits for treatment monitoring during the 12 weeks
Treatment - Period 3 (Treat-to-Target)
Duration - Up to 24 weeks
Participants who respond but still have symptoms receive combination therapy of stimulation and RA drug for up to 24 weeks.
Visits to monitor combination therapy during this period
Long-term Follow-up - Period 4
Duration - Up to 5 years
All participants are followed for up to 5 years to assess long-term safety and may receive standard of care treatments with or without stimulation.
Follow-up visits for long-term safety monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Similar Trials
Study of Vitamin E Supplementation to Reduce Inflammation and Symptoms in Women with Rheumatoid Arthritis
Using Advanced 7 Tesla MRI Brain Imaging to Understand How Filgotinib Relieves Pain in Adults with Rheumatoid Arthritis
Evaluating Safety and Dose Levels of MK-1045 in Adults with Lupus or Rheumatoid Arthritis
Phase 1 Study Evaluating Safety and Drug Behavior of CND319 in Healthy Adults and Patients with Rheumatic Diseases
Study of NKX019, a CAR NK Cell Therapy Targeting CD19, in Adults With Autoimmune Diseases
Phase 1b Open-label Trial to Assess Safety and Effects of Plamotamab Injection in Adults With Moderate to Severe Rheumatoid Arthritis
Phase 1b2 Study of AZD0120 Dual Targeting CAR T-cell Therapy in Adults with Autoimmune Diseases Including Systemic Sclerosis and Rheumatoid Arthritis
Phase I Study Evaluating Safety, Effectiveness, and Dosing of GNC-038 Antibody Injection for Rheumatoid Arthritis Treatment
Evaluation of Safety and Tolerability of Intravenous CPTX2309 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis or Systemic Lupus Erythematosus
Phase 1 Study of LY4298445 Safety and Tolerability in Healthy Adults and Adults With Systemic Lupus Erythematosus or Rheumatoid Arthritis
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.
Sander W Tas, Jeroen Christiaans, Maria J H Boumans...